Emmanuelle joined Novo Holdings A/S in September 2015 and is Partner at Seed Investments. She led several investment rounds and company creation efforts, and serves on the Boards of Corwave, Aloop, MinervaX, Draupnir, Heparegenix and BiOrigin.

Emmanuelle has more than 15 years of experience in venture capital investment. Prior joining Novo Seeds, Emmanuelle was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands.

Emmanuelle obtained her MSc degree from the Agrocampus Ouest (France) in 2003 and her PhD degree in 2006 from the Paris 7 University, for her work on the immunosuppressive properties of a bacterial toxin, conducted at Pasteur Institute (Paris, France). She also has a Specialized Master in pharmaceutical management from ESCP-EAP.